Intec Closes Merger with Decoy Biosystems
USA - English
Changes Corporate Name to Indaptus Therapeutics to Reflect Clinical Focus
News provided by
Share this article
Share this article
NEW YORK, Aug. 3, 2021 /PRNewswire/ Indaptus Therapeutics, Inc. (Nasdaq: INDP) ( Indaptus or the Company, and formerly, Intec Parent, Inc.) today announced the closing of its previously announced merger with Decoy Biosystems, Inc. ( Decoy ) and the completion of a $30 million private placement in accordance with the merger agreement. In addition, the Company announced a corporate name change to Indaptus Therapeutics, as it better reflects the Company s therapeutic focus.
Indaptus is expected to begin trading on the Nasdaq Capital Market at the open of trading on August 4, 2021, under the ticker symbol INDP and a new CUSIP number (45339J 105). The previous ticker symbol was NTEC (Nasdaq: NTEC). The Company will have a new website address: www.indaptusrx.com.
Intec Announces Expected Closing Date of Decoy Merger prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: PRA Health Sciences, Inc. (NASDAQ:.
Share this article
Share this article
NEW YORK, May 13, 2021 /PRNewswire/ Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
PRA Health Sciences, Inc. (NASDAQ: PRAH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to ICON plc. Under the terms of the transaction, PRA Health shareholders will receive $80.00 in cash and 0.4125 shares of ICON stock for each PRA Health share that they own.
WSFS Financial Corporation (NASDAQ: WSFS)
concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Bryn Mawr Bank Corporation. Under the terms of the agreement, stockholders of Bryn Mawr will receive 0.90 of a share of WSFS common stock for each share of Bryn Mawr common stock.
Intec Pharma Ltd. (NASDAQ: NTEC)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of
Intec Pharma Ltd. (NASDAQ: NTEC) in connection with the proposed acquisition of the company by Decoy Biosystems, Inc. ( Decoy ). Upon consummation of the transaction, NTEC s shareholders will own approximately 25% of the combined entity, with Decoy shareholders owning approximately 75%. If you own NTEC shares and wish to discuss this investigation or your rights, please call us or visit our website: https://weisslawllp.com/ntec/
RumbleOn, Inc. (NASDAQ: RMBL)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of